Tacrolimus has been shown to be superior to cyclosporine in the prevention of acute rejection in several randomized studies. However, few of these studies used paired kidneys for analysis. Moreover, most of the published data used whole blood trough levels for drug monitoring. Different studies have shown that the use of limited sampling strategy and abbreviated formula to estimate the 12-hour area under the concentration-time curve (AUC 0-12 ) allowed better prediction of drug exposure. Methods: A total of 66 Chinese first cadaveric renal transplant recipients received paired kidneys between 1 st June 1998 and 31 st December 2004. They were randomized to receive either tacrolimus-based (n = 33) or cyclosporine/Neoral-based therapies (n = 33). Abbreviated AUC 0-12 was used for drug monitoring and dose titration. The mean follow-up duration was 2.3 2.2 years. Results: Patient and graft survival were comparable. A lower incidence of acute rejection was observed in the tacrolimus group (15% vs 27.3%), although the difference was insignificant (p = 0.23). The creatinine clearance was significantly better in tacrolimus-treated patients beginning from 6 months until 5 years after transplantation. The prevalence of hypertension, post-transplant diabetes mellitus, infection and malignancy were similar in both groups. The prevalence of hypercholesterolemia (11/33 vs 4/33) and gum hypertrophy (6/33 vs 1/33) was higher in Neoraltreated patients (p = 0.04 for both). Conclusion: Renal function was significantly better in the tacrolimus group in this paired kidney analysis. The use of abbreviated AUC 0-12 provided a better tool for drug monitoring than traditional trough level measurement. Background: To review glomerular diseases diagnosed in allograft kidneys and to correlate them with clinical parameters. Methods: Eight hundred and ninety-one renal graft biopsies and 43 graft nephrectomies filed in Queen Mary Hospital from 1980 to 2004 were studied. They came from 442 allografts transplanted to 425 patients. Results: Glomerular diseases were diagnosed in 33.0% of kidney grafts. Indications for biopsy were baseline assessment (23 biopsies, 2.5%), renal dysfunction (790 biopsies, 88.7%), proteinuria (154 biopsies, 17.3%), hematuria (11 biopsies, 1.2%), and by protocol (4 biopsies, 0.4%). The median time post-transplant when the biopsies were procured was less than 8 months. The mean time post-transplant for diagnosing IgA nephropathy (IgAN), transplant glomerulopathy (TG), focal segmental glomerulosclerosis (FSG), mesangiocapillary glomerulonephritis (MCGN), membranous GN, mesangial proliferative GN, and diabetic nephropathy was 70, 66, 65, 55, 45, 49, and 101 months, respectively. Specific glomerular diseases were diagnosed by biopsies in 106 of 119 (89.1%) proteinuric allografts. Recurrent glomerular disease was documented in 31 (7.0%) grafts. Conclusion: Glomerulopathy was common in allograft biopsies. IgAN, TG, FSG, mesangial proliferative GN, and membranous GN comprised the majority. A higher proportion of grafts from donors related to the recipients than from unrelated donors had IgAN (p < 0.05), and there was no difference in the time to diagnose IgAN post-transplant between the two groups, suggesting that genetic factors might play a role in its pathogenesis. Recurrence of glomerulopathy underlying end-stage renal disease was frequent for IgAN, FSG, and MCGN, but this was rare for membranous GN. 
Background:
To review glomerular diseases diagnosed in allograft kidneys and to correlate them with clinical parameters. Methods: Eight hundred and ninety-one renal graft biopsies and 43 graft nephrectomies filed in Queen Mary Hospital from 1980 to 2004 were studied. They came from 442 allografts transplanted to 425 patients. Results: Glomerular diseases were diagnosed in 33.0% of kidney grafts. Indications for biopsy were baseline assessment (23 biopsies, 2.5%), renal dysfunction (790 biopsies, 88.7%), proteinuria (154 biopsies, 17.3%), hematuria (11 biopsies, 1.2%), and by protocol (4 biopsies, 0.4%). The median time post-transplant when the biopsies were procured was less than 8 months. The mean time post-transplant for diagnosing IgA nephropathy (IgAN), transplant glomerulopathy (TG), focal segmental glomerulosclerosis (FSG), mesangiocapillary glomerulonephritis (MCGN), membranous GN, mesangial proliferative GN, and diabetic nephropathy was 70, 66, 65, 55, 45, 49 , and 101 months, respectively. Specific glomerular diseases were diagnosed by biopsies in 106 of 119 (89.1%) proteinuric allografts. Recurrent glomerular disease was documented in 31 (7.0%) grafts. Conclusion: Glomerulopathy was common in allograft biopsies. IgAN, TG, FSG, mesangial proliferative GN, and membranous GN comprised the majority. A higher proportion of grafts from donors related to the recipients than from unrelated donors had IgAN (p < 0.05), and there was no difference in the time to diagnose IgAN post-transplant between the two groups, suggesting that genetic factors might play a role in its pathogenesis. Recurrence of glomerulopathy underlying end-stage renal disease was frequent for IgAN, FSG, and MCGN, but this was rare for membranous GN. 
Clinical Outcome of Hepatitis C Virus (HCV) Infection on Renal Transplantation

Background and Methods:
In order to understand the clinical outcome of HCV-infected renal allograft recipients, a retrospective review was conducted in July 2005 to study the clinical course of renal allograft recipients followedup in the renal unit of Princess Margaret Hospital since January 2002. Results: In 2002, 23 out of 404 renal transplant recipients were HCV-infected. The male: female ratio was 12:11; 82.6% of HCV-infected patients had cadaveric renal transplantation in China; 69.6% of HCV-infected patients were HCV-RNA positive. The predominant HCV genotype was 1b (56.3%). Other genotypes were: 1a, 18.8%; 2a, 12.5%; 3b, 6.2%; and 6a, 6.2%. Only two patients had cohepatitis B virus infection. Two patients had liver biopsy before transplantation; both showed features of chronic hepatitis but they had stable graft and liver functions. None of them had acute flare up of hepatitis or hepatocellular carcinoma. One patient developed liver cirrhosis, while two eventually resumed dialysis due to graft failure. The mortality rates of HCV-infected and non-HCVinfected renal allograft recipients were 17.4% and 1.6%, respectively. Four HCV-infected recipients died: two died of severe sepsis with multiple organ failure; one died of perforated bowel; and one died from an unknown cause. Conclusion: Although there is a higher mortality rate in HCV-infected renal allograft recipients, HCV infection is not a contraindication to renal transplantation. Transplantation is the best option for patients with HCV-infected end-stage renal failure. Adjustment of immunosuppression and careful followup are mandatory in order to detect infection and worsening of liver disease earlier. Background: Tacrolimus is a substrate for cytochrome P450 3A isoenzymes and P-glycoprotein encoded by MDR1. Polymorphisms in the CYP3A isoenzymes and MDR1 may play an important role in tacrolimus pharmacokinetics. We genotyped CYP3A and MDR1 polymorphisms and examined the association between these polymorphisms and the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Methods: An abbreviated AUC was calculated using limited blood sampling strategy in 50 Chinese renal transplant recipients. Genotypes were determined using realtime PCR FRET assays. The frequency and influence of MDR1 (C1236T, G2677T/A, C3435T), CYP3A4 (A-392G) and CYP3A5 (A6986G) polymorphisms on the dose-adjusted AUC (ng • hr/mL/mg/kg) and on the dose requirement (mg/kg/day) was analyzed using the non-parametric Kruskal-Wallis and the Mann Whitney U test. Results: The tacrolimus dose (mg/kg/day) was significantly higher in CYP3A5*1/*1 (10% of Chinese patients) or MDR1 2677TT carriers (20%) than in CYP3A5*3/*3 or MDR1 2677GG carriers [0.13 (0.05-0.18 mg/kg/day) vs 0.048 (0.01-0.09 mg/kg/day), p < 0.000] and [0.074 (0.05-0.11 mg/kg/day) vs 0.048 (0.03-0.09 mg/kg/day), p = 0.022], respectively. The dose-adjusted AUC was significantly lower in CYP3A5*1/*1 and MDR1 2677TT carriers than in CYP3A5*3/*3 and MDR 2677GG carriers. The other CYP3A and MDR1 polymorphisms were not associated with significant altered tacrolimus dosage. Conclusion: Renal transplant recipients carrying the CYP3A5*1/*1 or MDR1 2677TT genotype required a higher daily tacrolimus dose compared with those with a CYP3A5*3/*3 or MDR1 2677GG genotype to maintain the tacrolimus blood level within the therapeutic window.
Influence of MDR1 and CYP3A Gene Polymorphisms on Dosing and AUC of Tacrolimus in Chinese Renal Transplant Recipients
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